SSA
DYN icon

Schonfeld Strategic Advisors’s Dyne Therapeutics DYN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-415,927
Closed -$5.26M – 2177
2025
Q3 		$5.26M Buy
415,927
+82,474
+25% +$941K 0.03% 565
2025
Q2 		$3.17M Buy
333,453
+187,159
+128% +$2.06M 0.02% 757
2025
Q1 		$1.53M Buy
+146,294
New +$2.09M 0.01% 1087
2024
Q4 		– Sell
-36,352
Closed -$1.31M – 2100
2024
Q3 		$1.31M Sell
36,352
-78,843
-68% -$3.14M 0.01% 1066
2024
Q2 		$4.07M Sell
115,195
-154,562
-57% -$4.49M 0.03% 623
2024
Q1 		$7.66M Sell
269,757
-5,942
-2% -$134K 0.05% 474
2023
Q4 		$3.67M Buy
+275,699
New +$2.69M 0.02% 600

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Schonfeld Strategic Advisors's DYN Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 415,927 shares — an estimated $5.26M sold.

Schonfeld Strategic Advisors first reported a position in DYN in Q4 2023 and held it in 7 quarters. The position peaked at $7.66M in Q1 2024. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 415,927 Dyne Therapeutics shares in Q4 2025, an estimated $5.26M.
  • Schonfeld Strategic Advisors first reported a position in Dyne Therapeutics in Q4 2023 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Dyne Therapeutics position peaked at $7.66M in Q1 2024.
  • 232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.